Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Abahssain, Halima ^a   Kairouani, Mouna ^a   Gherman, Robert ^b   M'Rabti, Hind ^a   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b Division of Maternal and Foetal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ANTECEDENT VARIABLE; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CASE REPORT; FEMALE; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PATHOGENESIS; RADIATION DOSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SECOND CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PROGNOSIS; TAMOXIFEN;

EID: 77955371420     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-67     Document Type: Article

References (27)

1. Scully RE, Young RH, Clement PB. Sex cord-stromal tumors, granulosa cell tumors and secondary tumors. Atlas of Tumor Pathology, 3rd Series, Fascicle 23 1998, 169-188. Washington, DC, Armed Forces Institute of Pathology, Rosai J, Sobin LH, Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, 349-352.
2. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989, 1(8630):117-20. 10.1016/S0140-6736(89)91141-0, 2563046.
3. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989, 60(1):126-31. 2247327, 2679843.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86(7):527-37. 10.1093/jnci/86.7.527, 8133536.
5. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984, 36(4):245-76.
6. Gherman RB, Parker MF, Macri CI. Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Obstet Gynecol 1994, 84:717-719.
7. Arnould L, Franco N, Soubeyrand MS, Mege F, Belichard C, Lizard-Nacol S, Collin F. Breast carcinoma metastasis within granulosa cell tumor of the ovary: morphologic, immunohistologic, and molecular analyses of the two different tumor cell populations. Hum Pathol 2002, 33(4):445-8. 10.1053/hupa.2002.124038, 12055682.
8. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351:1451-1467. 10.1016/S0140-6736(97)11423-4, 9605801, Early Breast Cancer Trialists' Collaborative Group.
9. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300. 10.1016/S0140-6736(03)12342-2, 12559863.
10. IARC Tamoxifen. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Some Pharmaceutical Drugs 1996, 66:253-365. International Agency for Research on Cancer, Lyon, France.
11. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005, 97:375-384. 10.1093/jnci/dji057, 15741574.
12. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993, 53:3919-3924.
13. Carthew P, Edwards RE, Nolan BM, Martin EA, Heydon RT, White INH, Tucker MJ. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 2000, 21:793-797. 10.1093/carcin/21.4.793, 10753217.
14. Mäntylä E, Nieminen L, Karlsson S. Endometrial cancer induction by tamoxifen in the rat. Eur J Cancer 1995, 31(A suppl. 6):S14.
15. Phillips DH, Hewer A, Osborne MR, Cole KJ, Churchill C, Arlt VM. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 2005, 20(4):297-303. 10.1093/mutage/gei038, 15928012.
16. Jordan VC, Robinson SP. Species-specific pharmacology of antiestrogens: Role of metabolism. Fed Proc 1987, 46:1870-1874.
17. Buckely MMT, Goa KL. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989, 37:451-490. 10.2165/00003495-198937040-00004, 2661195.
18. Lonning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992, 52:4719-4723.
19. Kemp JV, Adam HK, Wakeling AE, Slater R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 1983, 32:2045-2052. 10.1016/0006-2952(83)90425-2, 6870933.
20. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992, 45(2):118-28. 10.1016/0090-8258(92)90273-L, 1592278.
21. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 1992, 10(6):990-4.
22. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992, 10(2):304-10.
23. Tucker MJ, Adam HK, Patterson HS, Laurence DR, McLean AEH, Weatherall M. Tamoxifen Safety testing of new drugs. Laboratory predictions and clinical performance. 1984, 125-61. New York: Harcourt, Brace and Jovanovich Publishers.
24. Welsh TH, Jia XC, Jones PB, Zhuang LZ, Hsueh AJ. Disparate effects of triphenylethylene antiestrogens on estrogen and progestin biosyntheses by cultured rat granulosa cells. Endocrinology 1984, 115(4):1275-82. 10.1210/endo-115-4-1275, 6434288.
25. Long GG, Cohen IR, Gries CL, Young JK, Francis PC, Capen CC. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol Pathol 2001, 29(6):719-26. 10.1080/019262301753386031, 11794385.
26. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996, 10:905-912.
27. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HC1, tamoxifen, estrogen, and alendronate. Bone 1996, 18:621-627. 10.1016/8756-3282(96)00085-3, 8806005.